The Targeted Degradation of BRAF V600E Reveals the Mechanisms of Resistance to BRAF-Targeted Treatments in Colorectal Cancer CellsAbygail G. Chapdelaine(University of Rhode Island), Marina K. Ayrapetov(University of Rhode Island)CancersDecember 12, 202310.3390/cancers15245805Cited by 10SaveCiteExport RISWatch citationsRelated PapersActivation of Hif1α by the Prolylhydroxylase Inhibitor Dimethyoxalyglycine Decreases Radiosensitivity|PLoS ONE|2011|41